Baidu
map

魏盟:第六医院心内科的现状与研究进展MedSci专访OCC2013:

2013-05-23 MedSci MedSci原创

第七届东方心脏病学会议(The 7th Oriental Congress of Cardiology,OCC 2013)于2013年5月23日在上海世博中心召开。本次会议由上海市医学会心血管病专科委员会主办,上海市十八家医院共同承办。本次大会历时3天,搭建了一个国际学术交流舞台,吸引来自全世界各地五千多位心血管和相关领域的专家、学者们齐聚一堂,共同探讨心血管疾病预防和治疗的各方面问题,演绎并交

第七届东方心脏病学会议(The 7th Oriental Congress of CardiologyOCC 2013)于2013523日在上海世博中心召开。本次会议由上海市医学会心血管病专科委员会主办,上海市十八家医院共同承办。本次大会历时3天,搭建了一个国际学术交流舞台,吸引来自全世界各地五千多位心血管和相关领域的专家、学者们齐聚一堂,共同探讨心血管疾病预防和治疗的各方面问题,演绎并交流世界心血管领域的最新进展。MedSci通讯员有幸采访了上海市第六医院心血管科魏盟教授。


MedSci通讯员:魏教授您好,感谢您接受MedSci的采访。上海市第六人民医院心血管科是国内最早开展心血管疾病的介入诊断治疗的专业学科之一,您作为学科带头人在国内的心内科领域具有较高的学术影响力,请您从学科建设方面谈谈贵科近年来取得的发展及成绩,在冠脉介入的临床与研究领域又取得了哪些可喜进展?

魏盟 谢谢,非常高兴接受你的采访。我们上海市第六医院心血管科确实也是个历史悠久的群体。国家心脏病学的创始人董承琅教授就是我们心内科的一个元老,是国家的著名教授,在他的引导下,我们科室这几年一直在寻求发展,虽然跟其他的兄弟学科相比,我们还有一些差距,但是整体上,我们这些年也取得了长足的进步。我们心内科目前百分之七八十的医生是具有硕士博士学位的,在临床的研究当中开展的介入手术各种各样,包括冠心病,瓣膜病,心肌病,先天性心脏病,以及电生理和起搏等等。在诊治的病人范围来讲,整个上海地区我们覆盖的人群大概是在100万左右。从08年开始做统计,每年增长的大概都是在百分之十几,不管是临床病例,还是手术病人,所以目前来讲,为患者提供了很方便的服务。

临床研究方面,我们重点关注的是心力衰竭相关的心内重构,还有这方面的动物实验,心肌保护临床实验,都在进行当中,包括SCI论文,今年我们科也发表了很多SCI文章,其中最高的影响因子10分。

为什么把心内重构,心内衰竭作为一个最主要的研究方向呢?因为是跟老龄化社会有关系的。在进入老龄化的社会中,心内衰竭是一个比较重要的疾病。心内衰竭的主要原因跟心肌梗死有关系,最终还是回到了冠心病。所以从这个疾病着手的话,其实也是对冠心病后期的保护,使它减少心力衰竭的发生率,是有一定的临床意义的。

 

关于魏盟教授:

上海市第六人民医院心内科主任,主任医师,教授,博导,医学博士,享受政府特殊津贴。1982年学士毕业于新疆石河子医学院医学系,1991年博士研究生毕业于上海医科大学。1995年、1997年曾在美国、德国学习介入心脏病学技术。学术任职为中华医学会心血管病分会委员,中华医学会心脏介入培训中心学术委员,上海医学会心血管病专科学会副主任委员,美国心脏病学会委员(FACC),美国胸科医师学会委员(FCCP)。担任中华心血管病杂志特约编委、临床心血管病、介入放射学、国际心血管病、Chest(中文版)、JACC(中文版)、中华老年多器官衰竭等杂志编委。主要从事冠心病、介入心脏病的临床工作和研究,有较高的造诣。曾承担及参与多项国家级、市部级科研课题,发表论文100多篇,主编《心血管疾病的诊断与鉴别诊断》、《内科急诊》,副主编《实用心脏病学》 4版专著1部。经桡动脉路径冠状动脉介入技术获上海市临床医疗成果三等奖,冠状动脉内多普勒导丝描记技术的临床应用获教育部科学技术进步二等奖。年曾在美国、德国学习介入心脏病学技术。学术任职为中华医学会心血管病分会委员,中华医学会心脏介入培训中心学术委员,上海医学会心血管病专科学会副主任委员,美国心脏病学会委员(FACC),美国胸科医师学会委员(FCCP)。担任中华心血管病编

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1703154, encodeId=5f9a1e031540b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Jun 29 04:50:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313222, encodeId=33e413132221e, content=<a href='/topic/show?id=694b508695d' target=_blank style='color:#2F92EE;'>#心内科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50869, encryptionId=694b508695d, topicName=心内科)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3679417, createdName=feather78, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352946, encodeId=938113529460d, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380382, encodeId=2c5d1380382fe, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605961, encodeId=bbd41605961de, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1703154, encodeId=5f9a1e031540b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Jun 29 04:50:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313222, encodeId=33e413132221e, content=<a href='/topic/show?id=694b508695d' target=_blank style='color:#2F92EE;'>#心内科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50869, encryptionId=694b508695d, topicName=心内科)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3679417, createdName=feather78, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352946, encodeId=938113529460d, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380382, encodeId=2c5d1380382fe, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605961, encodeId=bbd41605961de, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1703154, encodeId=5f9a1e031540b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Jun 29 04:50:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313222, encodeId=33e413132221e, content=<a href='/topic/show?id=694b508695d' target=_blank style='color:#2F92EE;'>#心内科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50869, encryptionId=694b508695d, topicName=心内科)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3679417, createdName=feather78, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352946, encodeId=938113529460d, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380382, encodeId=2c5d1380382fe, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605961, encodeId=bbd41605961de, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=)]
    2013-05-25 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1703154, encodeId=5f9a1e031540b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Jun 29 04:50:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313222, encodeId=33e413132221e, content=<a href='/topic/show?id=694b508695d' target=_blank style='color:#2F92EE;'>#心内科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50869, encryptionId=694b508695d, topicName=心内科)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3679417, createdName=feather78, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352946, encodeId=938113529460d, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380382, encodeId=2c5d1380382fe, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605961, encodeId=bbd41605961de, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1703154, encodeId=5f9a1e031540b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Jun 29 04:50:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313222, encodeId=33e413132221e, content=<a href='/topic/show?id=694b508695d' target=_blank style='color:#2F92EE;'>#心内科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50869, encryptionId=694b508695d, topicName=心内科)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3679417, createdName=feather78, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352946, encodeId=938113529460d, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380382, encodeId=2c5d1380382fe, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605961, encodeId=bbd41605961de, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 25 11:50:00 CST 2013, time=2013-05-25, status=1, ipAttribution=)]

相关资讯

沈卫峰:临床医生晋升考核标准应当多元化MedSci专访OCC2013:

第七届东方心脏病学会议(The 7th Oriental Congress of Cardiology,OCC 2013)于2013年5月23日在上海世博中心召开。本次会议由上海市医学会心血管病专科委员会主办,上海市十八家医院共同承办,本次大会上,MedSci有幸采访到本次大会执行主席沈卫峰院长。   MedSci通讯员:沈教授您好,非常感谢您抽出时间接受MedSci的专访。在刚刚

三位专家直击临床研究设计(新闻发布会)MedSci专访OCC2013:

第七届东方心脏病学会议(The 7th Oriental Congress of Cardiology,OCC 2013)于2013年5月23日在上海世博中心召开。本次会议由上海市医学会心血管病专科委员会主办,上海市十八家医院共同承办。 大会于5月23日下午15:00召开新闻发布会,MedSci就年轻医生如何进行高质量临床研究发表了提问。    MedSci通讯员

Baidu
map
Baidu
map
Baidu
map